| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
93-O17S is an ionizable cationic lipid that facilitates LNPs to target splenic tissue after systemic administration, though it does not have a traditional protein binding target.
|
|---|---|
| ln Vitro |
In cell-based assays, 93-O17S LNPs effectively delivered Cre recombinase mRNA to splenic cells, enabling successful Cre-mediated recombination. The LNP formulation also demonstrated efficient delivery of Cas9 single-guide RNA and ribonucleoproteins for genome editing applications. In B16/F10 murine melanoma models, LNPs containing 93-O17S delivered cGAMP intratumorally, enhancing cross‑presentation of tumor antigens and stimulating STING activation.
|
| ln Vivo |
93-O17S LNPs were administered intravenously to mice, resulting in targeted delivery of mRNA and ribonucleoproteins to the spleen, where successful genome editing was observed. In B16/F10 tumor models, intratumoral injection of cGAMP LNPs containing 93-O17S enhanced antigen cross‑presentation and triggered STING‑dependent immune responses.
|
| Enzyme Assay |
93-O17S is incorporated into LNPs via microfluidic mixing with lipid components (DSPC, cholesterol, PEG-lipid) and mRNA in an acidic buffer (pH 4). Its pKa (~6.8) enables pH-dependent ionization for efficient mRNA encapsulation and endosomal release. Lipidoid purity and particle size (sub-100 nm) are confirmed prior to use.
|
| Cell Assay |
In vitro cell uptake of 93-O17S LNPs is evaluated in splenocytes or HEK293 cells by incubating LNPs encapsulating fluorescent mRNA (e.g., Cy5-labeled) for 4-24 h. Cellular association is measured by flow cytometry, and protein expression (e.g., Cre recombinase) is quantified via Western blotting or reporter assays.
|
| Animal Protocol |
In vivo delivery is assessed by i.v. injection of LNPs (0.5‑2 mg/kg mRNA) into C57BL/6 mice. After 24‑72 h, splenic gene editing is analyzed by PCR or flow cytometry. For tumor models, intratumoral injection of cGAMP LNPs is performed, followed by assessment of STING pathway activation and tumor growth.
|
| ADME/Pharmacokinetics |
93-O17S LNPs are designed for rapid clearance from plasma and accumulation in the spleen with minimal hepatic retention. LNPs remain stable in serum for at least 6 h, enabling systemic circulation and distribution to secondary lymphoid organs, where pH-dependent ionization facilitates endosomal escape and mRNA release.
|
| Toxicity/Toxicokinetics |
No overt toxicity has been reported for 93-O17S at typical LNP doses. The lipidoid is well tolerated in mice, with no significant changes in body weight or serum biomarkers. This favorable safety profile, combined with effective splenic targeting, supports its use in vaccine and gene‑editing applications.
|
| References | |
| Additional Infomation |
93-O17S is an ionizable cationic lipid for LNP formulation enabling splenic mRNA delivery and genome editing. It has no reported clinical trials or regulatory approvals and is currently a preclinical research tool. As a synthetic lipidoid (C44H₈3N3O4S2, MW 782.28), it represents an emerging class of LNPs for non‑viral, tissue‑specific nucleic acid delivery with applications in cancer immunotherapy and genetic disease modeling.
|
| Molecular Formula |
C44H83N3O4S2
|
|---|---|
| Molecular Weight |
782.28
|
| Exact Mass |
781.582
|
| CAS # |
2227008-67-3
|
| PubChem CID |
155324003
|
| Appearance |
Light yellow to yellow ointment
|
| LogP |
14.6
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
44
|
| Heavy Atom Count |
53
|
| Complexity |
742
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCSCCOC(=O)CCN(CCCN1C=CN=C1)CCC(=O)OCCSCCCCCCCCCCCCCC
|
| InChi Key |
OLOIOPYNTGMAAP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C44H83N3O4S2/c1-3-5-7-9-11-13-15-17-19-21-23-25-38-52-40-36-50-43(48)28-33-46(31-27-32-47-35-30-45-42-47)34-29-44(49)51-37-41-53-39-26-24-22-20-18-16-14-12-10-8-6-4-2/h30,35,42H,3-29,31-34,36-41H2,1-2H3
|
| Chemical Name |
2-tetradecylsulfanylethyl 3-[3-imidazol-1-ylpropyl-[3-oxo-3-(2-tetradecylsulfanylethoxy)propyl]amino]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2783 mL | 6.3916 mL | 12.7831 mL | |
| 5 mM | 0.2557 mL | 1.2783 mL | 2.5566 mL | |
| 10 mM | 0.1278 mL | 0.6392 mL | 1.2783 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
